Amgen (BSP:AMGN34) Debt-to-Asset : 0.67 (As of Dec. 2023)

View and export this data going back to 2011. Start your Free Trial

What is Amgen Debt-to-Asset?

Amgen's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was R$7,070 Mil. Amgen's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was R$309,520 Mil. Amgen's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2023 was R$476,035 Mil. Amgen's debt to asset for the quarter that ended in Dec. 2023 was 0.67.

Amgen Debt-to-Asset Historical Data

The historical data trend for Amgen's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amgen Debt-to-Asset Chart

Amgen Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

0.50

0.52

0.55

0.60

0.67

Amgen Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Asset	Get a 7-Day Free Trial															0.60	0.69	0.68	0.67	0.67

Competitive Comparison of Amgen's Debt-to-Asset

For the Drug Manufacturers - General subindustry, Amgen's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Amgen's Debt-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Amgen's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Amgen's Debt-to-Asset falls into.

Amgen Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Amgen's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(7070.411	+	309520.366)	/	476035.169
	=	0.67

Amgen's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(7070.411	+	309520.366)	/	476035.169
	=	0.67

Amgen (BSP:AMGN34) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Amgen Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Amgen's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Amgen (BSP:AMGN34) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amgen Inc (BSP:AMGN34) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

AMGN:USA AMG N:Mexico AMGd:UK 0R0T:UK AMG:Germany AMGN:Austria AMGN:Argentina

Address

One Amgen Center Drive, Thousand Oaks, CA, USA, 91320-1799

Website

https://www.amgen.com

Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.

Amgen (BSP:AMGN34) Headlines

No Headlines